factual

Insulin-Intensive Patients Are Dexcom's Core Market

Dexcom's brand targets insulin-intensive diabetics who take basal plus mealtime insulin, about 4 million in the US and 10 million across Dexcom's current markets, while Abbott Libre dominates less intensive type 2 patients because it is cheaper and needs less real-time monitoring.

factualpending

Speaker

Aneal

Evidence Quote

“There's about 4 million of those patients in the US, 10 million in Dexcom's current markets. And Dexcom is viewed, based on the clinical data, as the most accurate CGM.”

Source

Dexcom: Digitizing Diabetes Management— Business Breakdowns
Created: 11/20/2026, 5:18:27 AM

Your notes

Loading notes...